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Diffuse midline glioma (DMG) with the H3K27M mutation is a lethal 
childhood brain cancer, with patients rarely surviving 2  years from diag-
nosis. We conducted a multi-site Phase 1 trial of the imipridone ONC201 for 
children with H3K27M-mutant glioma (NCT03416530). Patients enrolled 
on Arm D of the trial (n=24) underwent serial lumbar puncture (baseline, 
2, 6 months) for cell-free tumor DNA (cf-tDNA) analysis at time of MRI. 
Additionally, patients on all arms of the trial at the University of Michigan 
underwent serial plasma collection. CSF collection was feasible in this co-
hort, with no procedural complications. We collected 96 plasma samples 
and 53 CSF samples from 29 patients, including those with H3F3A (H3.3) 
(n=13), HIST13HB (H3.1) (n= 4), and unknown H3 status/not biopsied 
(n=12) [range of 0–8 CSF samples and 0–10 plasma samples]. We performed 
digital droplet polymerase chain reaction (ddPCR) analysis and/or amplicon-
based electronic sequencing (Oxford Nanopore) of cf-tDNA samples and 
compared variant allele fraction (VAF) to radiographic change (maximal 2D 
tumor area on MRI). Preliminary analysis of samples demonstrates a cor-
relation between changes in tumor size and H3K27M cf-tDNA VAF, when 
removing samples with concurrent bevacizumab. In multiple cases, early re-
duction in CSF cf-tDNA predicts long-term clinical response (>1 year) to 
ONC201, and does not increase in cases of later-defined pseudo-progression 
(radiation necrosis). For example, a now 9-year old patient with thalamic 
H3K27M-mutant DMG underwent treatment with ONC201 after initial 
radiation and developed increase in tumor size at 4 months post-radiation 
(124% baseline) of unclear etiology at the time. Meanwhile, her ddPCR 
declined from baseline 6.76% VAF to <1%, which has persisted, with now 
near complete response (15% tumor reduction) at 30 months on treatment 
from diagnosis. In summary, we present the feasibility and utility of serial 
CSF/plasma monitoring of a promising experimental therapy for DMG.
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Background: A Phase 1, single center study is ongoing to evaluate the condi-
tionally replicative oncolytic adenovirus, DNX-2401 (tasadenoturev), followed 
by radiotherapy (RT) in pediatric patients with newly diagnosed diffuse intrinsic 
pontine glioma (DIPG). Methods: Patients 1–18 years with newly diagnosed 
DIPG with no prior treatment, Lansky/Karnofsky performance score ≥ 70, and 
adequate organ function were enrolled. A tumor biopsy was performed followed 
by a single intratumoral injection of 1e10-5e10 virus particles (vp) DNX-2401. 
Conventional radiotherapy was initiated within 1  month of DNX-2401 ad-
ministration. Results: Enrolled subjects (n=12) had a median age of 9 (range 
3–18) and performance scores of 90–100 (n=4; 33%) or 70–80 (n=8; 67%). 
As part of a dose escalation design, subjects were treated with 1e10 vp (n=4) or 
5e10 vp DNX-2401 (n=8), which was then followed by standard RT in 11 of 
12 subjects (92%). No dose-limiting toxicities were observed and the treatment 
regimen was well-tolerated. Adverse events (AEs) have been primarily mild to 
moderate and consistent with underlying disease. The most commonly reported 
AEs (≥ 5 subjects), regardless of study drug relationship, include headache, as-
thenia, vomiting, anemia, leukocytosis, and fever. Two SAEs have been reported 
including grade 3 lymphopenia and grade 3 abdominal pain. Tumor reductions 
have been observed and efficacy evaluations are ongoing. As of 09Dec2020, 
12-month survival (OS-12) was 71% and 4 of 12 patients had survived > 
20 months. Four subjects continue to be followed for survival. Correlative ana-
lysis of tumor biopsy and peripheral samples is ongoing. Conclusions: DNX-
2401 followed by RT can be safely administered to pediatric subjects with newly 
diagnosed DIPG; clinical activity and preliminary survival are encouraging.
EPCT-05. A PHASE 1/2 STUDY OF AVAPRITINIB FOR KIT- OR 
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Prognosis for pediatric patients with advanced relapsed/refractory (R/R) 
solid (including central nervous system [CNS]) tumors is poor; targeted ther-
apies achieve response rates of only ~15%. Germ cell tumors and high-grade 
glioma (HGG) are the most common with KIT mutations; sarcoma and HGG 
are the most common tumors with platelet-derived growth factor receptor 
alpha (PDGFRA) mutations. Two-year overall survival is <10% for pediatric 
patients with diffuse intrinsic pontine glioma, often driven by PDGFRA mu-
tations. No KIT/PDGFRA targeted therapies are currently approved for pedi-
atric patients with R/R solid tumors. The selective KIT and PDGFRA inhibitor, 
avapritinib, demonstrated potent activity against KIT activation-loop (exon 
17), juxtamembrane (exon 11), and extracellular-domain (exon 9)  mutants 
(IC50 <2 nM), and PDGFRA activation-loop (D842V) mutants (IC50=0.24 nM). 
CNS penetration in preclinical models (brain-to-plasma ratios at steady-state 
ranging from 0.74–1.00) demonstrated potential for activity against CNS tu-
mors. Avapritinib is approved for the treatment of adults with unresectable/
metastatic gastrointestinal stromal tumors (GIST) harboring PDGFRA exon 
18 mutations (including D842V) in the USA based on an overall response rate 
³84% with 59% response durations >6 months, and in the EU for adults with 
unresectable/metastatic GIST harboring a PDGFRA D842V mutation. The 
objectives of this 2-part phase 1/2 multicenter, open-label study, anticipated 
to enroll 31 patients from Q3 2021, are to assess avapritinib safety, prelim-
inary efficacy, and pharmacokinetics in pediatric patients with KIT/PDGFRA-
mutant solid R/R tumors. Eligible patients are aged 2 to <18 years with no 
alternative treatment options. Part 1 will enroll ≥6 patients; primary endpoint 
is confirmed age and body surface area physiologically-based pharmacokinetic 
modeling dose to provide equivalent exposure to the 300 mg adult avapritinib 
dose. Part 2 will enroll ≥25 patients at the recommended modeled avapritinib 
dose from Part 1; primary endpoint is overall response rate. Avapritinib once-
daily will be administered in continuous 28-day cycles.
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Introduction: Precise diagnoses and robust detection of actionable alter-
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diagnostics, the Pediatric Targeted Therapy (PTT) 2.0 program aims at the 
improvement of diagnostic accuracy and detection of actionable alterations 
for pediatric high-risk patients. The impact of these analyses on clinical 
management is reported. Methods: Pediatric patients with relapsed or pro-
gressive tumors after standard of care treatment were included, independent 
of histological diagnosis. Formalin fixed paraffin embedded material and 
a blood sample for germline correction were requested. DNA methyla-
tion array, targeted gene panel sequencing (130 genes), RNA and Sanger 
sequencing in selected cases, and immunohistochemistry (IHC) of selected 
markers (pERK, pAKT, pS6, PD-L1) were performed. A questionnaire-based 
follow-up was used to determine the clinical impact of the analysis.  Re-
sults: We enrolled n=263 patients from February 2017 to February 2019. 
Complete molecular analysis was possible for n=260 cases (99%). The most 
common entities were brain tumors (n=172/260, 65%). In brain tumors, 
DNA methylation array alone allowed robust diagnostic classification (score 
of >=0.9) in n=104/172 cases (60%). Actionable targets as detected by copy 
number calculation, gene panel sequencing, RNA sequencing and IHC were 
found in n=94/172 (55%) brain tumor cases. The most common actionable 
targets in brain tumors were MAPK (pERK, BRAF fusions, BRAF V600E), 
mTOR (pS6), PI3K (pAKT), CDK4/6 (CDKN2A/B loss), and immune check-
points (PD-L1). Pathogenic germline alterations with clinical relevance were 
identified in n=12/172 brain tumor cases (6.9%) and were confirmed by 
Sanger sequencing, 5/12 (41%) of which were previously unknown. Clin-
ical follow-up of subsequent treatment and outcome are ongoing. Conclu-
sion: The combination of next-generation diagnostics such as methylation 
arrays and targeted sequencing in addition to selected IHC markers added 
robust information with regard to diagnosis and actionable alterations. The 
impact on clinical decision-making and on outcome is currently being evalu-
ated.
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Diffuse intrinsic pontine gliomas (DIPGs) are lethal pediatric brain tumors 
with no effective therapies beyond radiation. The highly invasive nature of 
DIPG is key to its aggressive phenotype, but the factors and mechanisms 
contributing to this aggressive invasion are unknown. Inhibitor of DNA 
binding (ID) proteins, key regulators of lineage commitment during embryo-
genesis, are implicated in tumorigenesis in multiple human solid tumors. 
Prior work showed that recurrent H3F3A and ACVR1 mutations increase 
ID1 expression in cultured astrocytes. However, the impact and targetability 
of ID1 have not been explored in human DIPG. Exome and transcriptome 
sequencing analyses of multi-focal DIPG tumors and normal brain tissue 
from autopsy (n=52) revealed that ID1 expression is significantly elevated 
in DIPG samples. Higher ID1 expression correlates with reduced survival 
in DIPG patients and increased regional invasion in multi-focal autopsy 
samples. Analyses of developing mouse brain RNA/ChIP-Seq data revealed 
high ID1 expression and H3K27ac promoter binding in prenatal hindbrain 
compared to all other prenatal and postnatal brain regions. ChIP-qPCR 
for H3K27ac and H3K27me3 revealed that ID1 gene regulatory regions 
are epigenetically poised for upregulation in DIPG tissues compared to 
normal brain, regardless of H3/ACVR1 mutational status. These data sup-
port that the developing pons is regionally poised for ID1 activation. Gen-
etic (shRNA) ID1 knockdown of primary human H3.3K27M-DIPG cells 
(DIPG007) resulted in significantly reduced invasion/migration and sig-
nificantly improved survival of K27M-DIPG mice. Knockdown of ID1 in 
DIPG cells also resulted in down-regulation of the WNK1-NKCC1 pathway, 
which regulates tumor cell electrolyte homeostasis and migration. Finally, 
treatment of DIPG007 cells with cannabidiol (CBD) reduced ID1 levels, 
viability of DIPG cells and significantly improved survival of K27M-DIPG 
mice. In summary, our findings indicate that multifactorial (genetic and re-
gional) epigenetic upregulation of ID1 drives DIPG invasiveness; and that 
targeting ID1 with CBD could potentially be an effective therapy for DIPG.
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Ruman Rahman1, David Walker1, Emma Campbell1, and 
Kristian Aquilina2; 1The University of Nottingham, Nottingham, UK, 
2Great Ormond Street Hospital, London, UK
Introduction: Brain tumours are the biggest cancer killer in children and 
young adults. Several recent developments have the potential to change the 
treatment of brain tumours in children. These include ultrasound-mediated 
blood-brain barrier disruption, convection enhanced delivery, polymer de-
livery systems and electric field therapy, as well as intra-arterial, intra-CSF 
and intra-nasal chemotherapy. To date, there have been very few clinical 
trials to evaluate any of these. The science and technology underlying these 
developments is not traditionally embedded within the standard paediatric 
neuro-oncology network. In addition, custom-built hardware, novel sur-
gical procedures and, in some cases, the testing and licensing of implantable 
devices, add difficulty at the regulatory level. Methods: The authors par-
ticipated in an international workshop funded by the charity Children 
with Cancer UK in 2016, where different experimental techniques aimed 
at optimising CNS drug delivery were discussed. Following this workshop 
and two subsequent workshops run by the CBTDDC (Children’s Brain Tu-
mour Drug Delivery Consortium) in 2018 and 2020, the CBTDDC and the 
recently developed ITCC (Innovative Therapies for Children with Cancer) 
brain tumour group started working together to set up a new initiative. This 
aims to develop CNS-delivery-focused trial working groups for paediatric 
brain tumours.  Results: We have assembled a prestigious steering group, 
comprising international researchers and clinicians with expertise in diverse 
aspects of translational and clinical research in CNS drug delivery. At our 
first group meeting in March, participants will discuss the most effective 
ways of translating the emerging drug delivery modalities into clinical trials. 
Prioritised actions will be taken forward and the group will reconvene to 
discuss developments and next steps at a workshop in the Autumn. Con-
clusion: We present this abstract to the SNO Paediatric conference to raise 
awareness of this initiative with the large number of relevant stakeholders 
who will be attending the event.
EPCT-09. CNS LEVELS OF PANOBINOSTAT IN A NON-
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Adequate exposure (effective concentration over time) of a therapeutic 
agent at its site of action is essential for antitumor efficacy. Given constraints 
of repeat tissue sampling, non-human primate models predictive of pharma-
cokinetics in pediatric patients have been utilized to assess central nervous 
system (CNS) exposure. Assessment of cerebrospinal fluid (CSF) drug levels 
have been used to extrapolate CNS penetration but the relationship of 
CSF drug levels with tissue distribution is unclear. Utilizing microdialysis, 
we previously demonstrated geographic variability of drug permeability 
across the blood:brain barrier (BBB), but this technique is complex and 
has a high standard deviation. We, therefore, explored a novel technique, 
matrix-assisted laser desorption/ionization mass spectrometry imaging 
(MALDI MSI), to compare plasma, CSF, and tissue drug levels in a terminal 
non-human primate model. Panobinostat, an HDAC inhibitor in clinical 
trials for DIPG/DMG, was selected for study as it has previously demon-
strated poor CNS tissue penetration but suggested modest clinical activity. 
Methods: Panobinostat (p.o., dose 1.6  mg/kg) was administered to 
non-tumor bearing primates (n=2). One hour following administration 
(Tmax), blood and CSF were collected, the animal euthanized, brain and 
spinal cord extracted, and immediately frozen at -80. Panobinostat distribu-
tion was mapped on ex vivo sagittal tissue sections using MALDI MSI. To 
provide specificity and degree of permeability, anatomical structures were 
segmented for analysis to determine drug concentrations. Blood, CSF and 
tissue levels of panobinostat were measured via LC-MS/MS. Results: Seg-
mentation analysis revealed quantifiable panobinostat, particularly in the 
lateral ventricles and choroid plexus, and also in the subventricular zone 
and brainstem, although the overall panobinostat concentration was below 
the limit of quantitation in these areas. Conclusions: Although not reflected 
in CSF PK, panobinostat is widely distributed in brain tissue. MALDI MSI 
allows regional assessment of panobinostat penetration and complements 
CSF pharmacokinetics.
EPCT-10. DEBIO1347, AN ORAL FGFR INHIBITOR: RESULTS FROM 
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Background: Oncogenic driver alterations in FGFR are present in a subset 
of pediatric gliomas. Debio1347 is an orally available, highly selective FGFR 
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